Burjassot
Burjassot
Burjassot, Valencia, Spain8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06571045 | |
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | NCT03683251 | |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06541704 | |
| Perpetual Observational Study - Ventilator Associated Pneumonia | Disease Attributes, Healthcare-Associated Pneumonia, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pneumonia, Ventilator-Associated, iatrogenic disease, lung disorder, nosocomial infection, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Not stated | 2026-09-10 | NCT05719259 | |
| A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | Geographic Atrophy Secondary to Age-related Macular Degeneration | Recruiting | Phase 2 | 2026-09-09 | NCT07441642 | |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Skin and Connective Tissue Diseases, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, skin disorder, subacute cutaneous lupus erythematosus | Active, not recruiting | Phase 2 | 2026-08-28 | NCT06980805 | |
| Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-27 | NCT05492578 | |
| Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material | age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 4 | 2026-05-28 | NCT07403825 |